Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy.
Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients.
ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs of the European Commission. The research aims to evaluate the protection of the immunotherapeutic VTP-800 in combination with an anti-PD-1 agent, and the reduction of serum prostate-specific antigen (PSA) levels as a surrogate biomarker used to determine the effectiveness of prostate cancer treatments.
The VTP-800 consists of the Vaccitech Chimpanzee Adenovirus Oxford 1 vector (PRIME) encoding the oncofetal antigen 5T4 (ChAdOx.5T4), followed by the Modified Vaccinia Ankara vector (BOOST) encoding the same antigen (MVA.5T4) in a heterologous primary boost.